AHT Corporation Reports Preliminary Q4 1999 Revenues; Company Retains Gruntal &Co., LLC As Financial Advisor.

Business Editors

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 10, 2000

AHT Corporation (Nasdaq:AHTC) reported today that it expects its 1999 fourth-quarter revenues to total approximately $450,000. This compares to $213,000 for the third quarter in 1999. The revenues in the fourth quarter for the Company's Dr. Chart(R) laboratory product, accounting for virtually all of its total revenues, did not reach the level previously anticipated, due in large measure to the Y2K preparation efforts of certain hospitals and Integrated Delivery Networks (IDNs) during this period. Certain hospitals and IDNs with which AHT was negotiating deferred their purchase decisions until 2000 and certain other hospital-affiliated laboratories slowed installation of Dr. Chart, delaying recognition of AHT's contract backlog revenues. The Company now has approximately $1.3 million relating to Dr. Chart contract backlog, which it expects to recognize in 2000. &uot;It's our belief,&uot; stated Jon Edelson, MD, Chairman, CEO and President of AHT Corporation, &uot;that AHT's revenues for the 1999 fourth quarter significantly understate the future potential for both our laboratory and prescription e-commerce products.&uot;

Business Outlook

Dr. Chart Laboratory Product

On the laboratory management side of its business during the fourth quarter, the Company worked on 21 customer installations and, of these, 11 product installations were completed. Based on its review of these installations, management concluded that not all of these installations met the criteria for revenue recognition in the quarter. The Company expects the criteria for revenue recognition will be met during this year.

&uot;As a clear indication of the potential for our business going forward,&uot; Dr. Edelson said, &uot;AHT has a substantial sales pipeline of Dr. Chart customers, many of which deferred purchase decisions to 2000 due to Y2K preparations. We expect to begin conversion of that pipeline to sales in this quarter, with announcements of these contracts beginning in this quarter. AHT is in contract negotiations with not only hospital-affiliated laboratories but also with national laboratories and national distribution channels that can provide our Company with access to physician desktops.&uot;

@Rx(TM) Prescription Management Service

&uot;On the prescription side of our business,&uot; Dr. Edelson said, &uot;the fourth quarter was an exciting one for AHT. We launched what we believe is the industry's first Internet prescription management service, @Rx, and promptly followed that launch by signing contracts for transaction-based business with leading national companies such as Merck-Medco Managed Care, drugstore.com, and PlanetRx.com. And last month, @Rx transmitted the nation's first electronic prescription to an online pharmacy.&uot; With respect to sales activity, Dr. Edelson noted that AHT is in contract negotiations with additional pharmacy benefit managers, pharmacies and national distribution channels having access to thousands of physician desktops. &uot;We also anticipate that the value of AHT's patents for the electronic management of prescriptions in the physician office is increasing as both the federal government and the e-commerce industry are embracing electronic prescribing as a means to significantly reduce the incidences of medication errors caused by illegible prescriptions and prescriptions that trigger adverse drug reactions. While still small, the royalties the Company received for its patents increased substantially in the fourth quarter from the previous period. We believe @Rx and AHT's patents will contribute an increasing portion of our Company's overall revenues beginning in 2000.&uot;

2000 Revenue Target

&uot;Given the pace of business activity so far this year for our Dr. Chart product and the increasing traction for @Rx, we believe the Company's 2000 revenue target of between $8 million and $8.5 million is achievable,&uot; Dr. Edelson stated. &uot;We base that assessment, in part, on approximately $1.3 million of contract backlog and our sales pipeline to date of approximately $4.7 million that represents advanced discussions and contract negotiations. Bear in mind that these amounts do not include incremental revenues we expect to generate from national transaction contracts currently in place or in negotiation or early-stage discussions that are not included in the aforementioned sales pipeline. Importantly, we believe the transaction-based platform of our products, combined with the national customers and national distribution channels that are secured and installed in 2000, have every potential to yield significant revenue growth for AHT in 2001.&uot;

Gruntal &Co., LLC Retained As Financial Advisor

AHT announced today that it has retained investment bank Gruntal &Co., LLC as a financial advisor to assist the Company with financing alternatives. AHT is holding discussions with healthcare e-commerce companies and financial institutions relating to the interest they have expressed in possibly establishing a minority equity position in the Company. At December 31, 1999, the Company's cash position was approximately $4.4 million, which included approximately $1.7 million of restricted cash.

Conference Call

AHT's management will hold a conference call tomorrow (Friday, February 11) at 8:45 am (Eastern Time) to review today's announcement. The dial-in number for the call is 800-482-5519 and the call ID number is 665547. Tomorrow morning's call is also being Web-cast on AHT's site at www.ahtech.com. The call will be available on replay through Friday, February 18, either by dialing 800-625-5288 (same ID number) or by accessing AHT's Web site. The Company expects to report its completed audited financial results for 1999 in March when it files its Form 10-K.

AHT Corporation (Nasdaq: AHTC) is a leading national provider of Internet-based clinical e-commerce among physicians, other healthcare providers and healthcare organizations. The Company provides information technology enabling the electronic management of laboratory and prescription transactions. AHT's customer base is comprised of some of the nation's leading hospital systems, national and regional laboratories, pharmacy benefit managers and pharmacies. For more information, please visit AHT's Web site at www.ahtech.com.

This press release contains forward-looking information regarding AHT Corporation. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, anticipated capital, anticipated transactions, planned product development, and products or service line growth may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the clinical e-commerce industry to develop at anticipated rates, failure of the Company's clinical information technology products and services and planned products to gain significant market acceptance, contracts not materializing, failure to obtain necessary financing, customer delay in installing new systems because of their Y2K-related issues, delays in customer acceptance of AHT software, competition and other economic factors. These forward-looking statements speak only as of the date hereof, and the Company disclaims any intention or obligations to update these forward-looking statements in the future. Additional risks and uncertainties are described in AHT's public filings with the Securities and Exchange Commission.